[go: up one dir, main page]

MX2018005867A - Integracion de las caracteristicas tumorales con el indice de cancer de mama. - Google Patents

Integracion de las caracteristicas tumorales con el indice de cancer de mama.

Info

Publication number
MX2018005867A
MX2018005867A MX2018005867A MX2018005867A MX2018005867A MX 2018005867 A MX2018005867 A MX 2018005867A MX 2018005867 A MX2018005867 A MX 2018005867A MX 2018005867 A MX2018005867 A MX 2018005867A MX 2018005867 A MX2018005867 A MX 2018005867A
Authority
MX
Mexico
Prior art keywords
breast cancer
integration
methods
subject
tumor characteristics
Prior art date
Application number
MX2018005867A
Other languages
English (en)
Inventor
Zhang Yi
A Schnabel Catherine
Original Assignee
Biotheranostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotheranostics Inc filed Critical Biotheranostics Inc
Publication of MX2018005867A publication Critical patent/MX2018005867A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)

Abstract

Se proporcionan métodos para determinar el riesgo de recurrencia de un cáncer de mama de un sujeto. También se proporcionan métodos para predecir la capacidad de respuesta a una terapia de cáncer de mama de un sujeto. Además, se proporcionan métodos para recomendar el tratamiento de un sujeto que tenga cáncer de mama. También se proporcionan métodos para tratar un sujeto que tenga cáncer de mama. Se proporcionan también sistemas para llevar a cabo los métodos descritos.
MX2018005867A 2015-11-13 2016-11-11 Integracion de las caracteristicas tumorales con el indice de cancer de mama. MX2018005867A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562255260P 2015-11-13 2015-11-13
US201562265964P 2015-12-10 2015-12-10
PCT/US2016/061568 WO2017083675A1 (en) 2015-11-13 2016-11-11 Integration of tumor characteristics with breast cancer index

Publications (1)

Publication Number Publication Date
MX2018005867A true MX2018005867A (es) 2018-09-21

Family

ID=58690472

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005867A MX2018005867A (es) 2015-11-13 2016-11-11 Integracion de las caracteristicas tumorales con el indice de cancer de mama.

Country Status (6)

Country Link
US (3) US11530448B2 (es)
EP (1) EP3374526A4 (es)
CO (1) CO2018004882A2 (es)
IL (1) IL259241B2 (es)
MX (1) MX2018005867A (es)
WO (1) WO2017083675A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108492884A (zh) * 2018-02-08 2018-09-04 浙江大学 基于Logistic回归模型的胰腺神经内分泌肿瘤淋巴结转移预测系统
CN108364106A (zh) * 2018-02-27 2018-08-03 平安科技（深圳）有限公司 一种报销单风险预测方法、装置、终端设备及存储介质
CN109272843A (zh) * 2018-11-23 2019-01-25 神农架林区人民医院 用于乳腺触诊的模拟训练装置
US20240418722A1 (en) 2021-04-06 2024-12-19 Institut Curie Methods and kits for diagnosing cancer and predicting response to treatment based on cenp-a labelling
EP4334475A1 (en) * 2021-05-07 2024-03-13 Agendia N.V. Endocrine treatment of hormone receptor positive breast cancer typed as having a low risk of recurrence
WO2024243328A2 (en) * 2023-05-22 2024-11-28 Board Of Regents, The University Of Texas System Methods and compositions for diagnosing, treating, and/or preventing inflammatory breast cancer

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981783A (en) 1986-04-16 1991-01-01 Montefiore Medical Center Method for detecting pathological conditions
US5545522A (en) 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
US6482600B1 (en) 1998-05-07 2002-11-19 Lifespan Biosciences, Inc. Breast cancer associated nucleic acid sequences and their associated proteins
WO2000029044A2 (en) 1998-11-13 2000-05-25 Pro Duct Health, Inc. Devices and methods to identify ductal orifices during nipple aspiration
US20030064072A9 (en) 1999-03-12 2003-04-03 Rosen Craig A. Nucleic acids, proteins and antibodies
US6642009B2 (en) 1999-05-17 2003-11-04 Cytyc Health Corporation Isolated ductal fluid sample
WO2001053450A1 (en) 2000-01-21 2001-07-26 Thomas Jefferson University Nipple aspirate fluid specific microarrays
EP1297002A2 (en) 2000-06-30 2003-04-02 Board Of Regents, The University Of Texas System Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery
EP1307738A2 (en) 2000-07-28 2003-05-07 Cytyc Health Corporation Cytological evaluation of breast duct epithelial cells retrieved by ductal lavage
WO2002026195A2 (en) 2000-09-29 2002-04-04 Clinomics Biosciences, Inc. Oncology tissue microarrays
US6794141B2 (en) 2000-12-22 2004-09-21 Arcturus Bioscience, Inc. Nucleic acid amplification
WO2002101075A2 (en) 2001-06-13 2002-12-19 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
WO2002103320A2 (en) 2001-06-18 2002-12-27 Rosetta Inpharmatics, Inc. Diagnosis and prognosis of breast cancer patients
WO2003004989A2 (en) 2001-06-21 2003-01-16 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US7622260B2 (en) 2001-09-05 2009-11-24 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
US20030198972A1 (en) 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
US7465553B2 (en) 2001-12-31 2008-12-16 Dana-Farber Cancer Institute, Inc. Psoriasin expression by breast epithelial cells
CA2530738C (en) 2003-06-24 2020-01-21 Genomic Health, Inc. Prediction of likelihood of cancer recurrence
ES2651849T3 (es) 2003-07-10 2018-01-30 Genomic Health, Inc. Algoritmo del perfil de expresión y test para el pronóstico del cáncer
AU2004274973A1 (en) 2003-09-19 2005-03-31 Aviaradx, Inc. Predicting breast cancer treatment outcome
US7504214B2 (en) 2003-09-19 2009-03-17 Biotheranostics, Inc. Predicting outcome with tamoxifen in breast cancer
US9856533B2 (en) 2003-09-19 2018-01-02 Biotheranostics, Inc. Predicting breast cancer treatment outcome
JP2008501346A (ja) 2004-06-04 2008-01-24 アビアラデックス，インコーポレイティド がんに関する遺伝子ｈｏｘｂ１３の重要性
JP2008539737A (ja) 2005-05-13 2008-11-20 ユニヴェルシテ リブル ドゥ ブリュッセル 遺伝子に基づくアルゴリズム的ガン予後
EP2365092A1 (en) 2005-06-03 2011-09-14 Aviaradx, Inc. Identification of tumors and tissues
EP2195467B1 (en) 2007-09-06 2016-12-14 bioTheranostics, Inc. Tumor grading and cancer prognosis in breast cancer
ES2667547T3 (es) 2010-12-09 2018-05-11 Biotheranostics, Inc. Pronóstico de cáncer de mama después del tratamiento
WO2013070521A1 (en) 2011-11-08 2013-05-16 Genomic Health, Inc. Method of predicting breast cancer prognosis
CA2923166A1 (en) 2013-09-09 2015-03-12 British Columbia Cancer Agency Branch Methods and kits for predicting outcome and methods and kits for treating breast cancer with radiation therapy
ES2829912T3 (es) 2013-09-11 2021-06-02 Bio Theranostics Inc Predecir la reaparición de cáncer de mama
US10253369B2 (en) 2014-05-29 2019-04-09 Biotheranostics, Inc. Predicting likelihood of response to combination therapy

Also Published As

Publication number Publication date
CO2018004882A2 (es) 2018-08-10
EP3374526A4 (en) 2019-09-11
US20230083179A1 (en) 2023-03-16
WO2017083675A1 (en) 2017-05-18
IL259241A (en) 2018-07-31
US20170137891A1 (en) 2017-05-18
BR112018009528A2 (pt) 2018-11-06
US11530448B2 (en) 2022-12-20
IL259241B2 (en) 2024-04-01
IL259241B1 (en) 2023-12-01
US20250215506A1 (en) 2025-07-03
EP3374526A1 (en) 2018-09-19
US12215390B2 (en) 2025-02-04

Similar Documents

Publication Publication Date Title
MX2018005867A (es) Integracion de las caracteristicas tumorales con el indice de cancer de mama.
IL260935A (en) Methods for treating hrg, her2-, er breast cancer using combined treatments that include an anti-erbb3 antibody
GEP20217331B (en) Anti-tigit antibodies
MX2016007282A (es) Modulador del receptor de estrogenos para el tratamiento de cancer de mama positivo al receptor de estrogenos localmente avanzado o metastasico.
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
TW201611847A (en) Compounds and compositions for treating EGFR expressing tumors
MX2017004715A (es) Anticuerpos anti-ox40 humanizados y usos de los mismos.
MX2015007185A (es) Uso de eribulina en el tratamiento de cancer de pecho.
IL244421A0 (en) Methods and kits for predicting outcome, and methods and kits for treating breast cancer with radiation therapy
PH12019500135A1 (en) Methods of treating prostate cancer
MX2017007707A (es) Metodo para predecir respuesta a agentes terapeuticos de cancer de mama y metodo de tratamiento de cancer de mama.
MX2017012824A (es) Tratamiento de cáncer de pulmón con inhibidores de glutaminasa.
MY180834A (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
MX2021002014A (es) Metodo para determinar el riesgo de recidiva de cancer de mama.
MX2019006331A (es) Métodos para tratar el cáncer usando anticuerpos anti-pd-l1 y antiandrógenos.
MX375557B (es) Método para predecir el resultado de un tratamiento con aflibercept de un paciente que se sospecha que padece un cáncer.
PH12016500580B1 (en) Conjugated antibodies against ly75 for the treatment of cancer
JO3541B1 (ar) علاجات طبية قائمة على اناموريلين
MX2016015163A (es) Biomarcadores mit y metodos para su uso.
EA201890868A1 (ru) Бактерии с ослабленной вирулентностью для лечения злокачественных солидных опухолей
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.
BR112016015595A2 (pt) métodos de determinação de câncer de pulmão
SI3302551T1 (sl) Metode zdravljenja predhodno nezdravljenega her2-pozitivnega metastatskega raka dojk
MX2017006201A (es) Respuesta de prediccion a un antagonista de vegf.
MX2017009857A (es) Isoformas delta133p53beta y delta133p53gamma son biomarcadores de celulas madre cancerosas.